Cargando…

Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics

Clinical practice guidelines (CPGs) translate evidence into recommendations to improve patient care and outcomes. To provide an overview of schizophrenia CPGs, we conducted a systematic literature review of English-language CPGs and synthesized current recommendations for the acute and maintenance m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Correll, Christoph U., Martin, Amber, Patel, Charmi, Benson, Carmela, Goulding, Rebecca, Kern-Sliwa, Jennifer, Joshi, Kruti, Schiller, Emma, Kim, Edward
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873492/ https://www.ncbi.nlm.nih.gov/pubmed/35210430 http://dx.doi.org/10.1038/s41537-021-00192-x

Ejemplares similares

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics
por: Pilon, Dominic, et al.
Publicado: (2021)

Racial and Ethnic Disparities in Long-Acting Injectable Antipsychotic Use in a National Sample of Medicare Beneficiaries With Schizophrenia
por: Li, Pengxiang, et al.
Publicado: (2023)

Clinical predictors of therapeutic response to antipsychotics in schizophrenia
por: Carbon, Maren, et al.
Publicado: (2014)

Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations
por: Anderson, Jeffrey P., et al.
Publicado: (2017)

Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies
por: Correll, Christoph U., et al.
Publicado: (2023)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

T232. EFFICACY AND SAFETY OF ANTIDEPRESSANT AUGMENTATION OF ANTIPSYCHOTICS IN SCHIZOPHRENIA
por: Galling, Britta, et al.
Publicado: (2018)

The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study
por: Mahabaleshwarkar, Rohan, et al.
Publicado: (2021)

Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation
por: Dickson, Matthew C., et al.
Publicado: (2022)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
por: Tiihonen, Jari, et al.
Publicado: (2019)

Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) study
por: Basu, Anirban, et al.
Publicado: (2022)

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
por: Kane, John M., et al.
Publicado: (2021)

O7.2. BREAKTHROUGH ON ANTIPSYCHOTIC MAINTENANCE MEDICATION IN A CLINICAL COHORT
por: Rubio, Jose, et al.
Publicado: (2018)

Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation
por: Loebel, Antony, et al.
Publicado: (2015)

The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia
por: Davidson, Michael
Publicado: (2018)

Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs
por: Bossie, Cynthia A., et al.
Publicado: (2015)

Real-world analysis of insurance churn among young adults with schizophrenia using the Colorado All-Payer Claims Database
por: Pesa, Jacqueline, et al.
Publicado: (2022)

Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2022)

Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review
por: CORRELL, Christoph U., et al.
Publicado: (2016)

The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia
por: Joshi, Kruti, et al.
Publicado: (2018)

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
por: Correll, Christoph U., et al.
Publicado: (2022)

Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics
por: Lafeuille, Marie-Hélène, et al.
Publicado: (2018)

Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia
por: Basu, Anirban, et al.
Publicado: (2023)

Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review
por: Coles, Alexandria S., et al.
Publicado: (2021)

The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research
por: Potkin, Steven G., et al.
Publicado: (2020)

T234. BREAKTHROUGH ON ANTIPSYCHOTIC MAINTENANCE MEDICATION: A STUDY-LEVEL META-ANALYSIS AND META-REGRESSION ANALYSIS
por: Rubio, Jose, et al.
Publicado: (2018)

Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
por: Litman, Robert, et al.
Publicado: (2023)

Associations Between Relapses and Psychosocial Outcomes in Patients With Schizophrenia in Real-World Settings in the United States
por: Lin, Dee, et al.
Publicado: (2021)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
por: Vasiliu, O.
Publicado: (2022)

Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic
por: Pilon, Dominic, et al.
Publicado: (2017)

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study
por: Citrome, Leslie, et al.
Publicado: (2013)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
por: Sajatovic, Martha, et al.
Publicado: (2018)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
por: Correll, Christoph U, et al.
Publicado: (2019)

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
por: Milz, Ruth, et al.
Publicado: (2023)

Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia
por: Pilon, Dominic, et al.
Publicado: (2017)

Pharmacologic treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2010)

A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia
por: Lin, Dee, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iv5obm1r8fm0i6mb2dtmp1bkjn